Evidence map›Paper›PMID 34689571›Full record

ArticleCirculation. Heart failure2021

FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions.

Juan B Ivey-Miranda, Brendan Stewart, Zachary L Cox, Wendy McCallum, Christopher Maulion, Olyvia Gleason, Grace Meegan, Jonathan G Amatruda, Julieta Moreno-Villagomez, Devin Mahoney and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Review
  6. sFlt-1 in Chronic Kidney Disease: Friend or Foe?International journal of molecular sciences · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Juan B Ivey-MirandaDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.
Brendan StewartDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0003-3490-1627
Zachary L CoxDepartment of Pharmacy, Lipscomb University College of Pharmacy, Nashville, TN (Z.L.C.).ORCID 0000-0002-4919-0146
Wendy McCallumDivision of Nephrology, Tufts Medical Center, Boston, MA (W.M.).
Christopher MaulionDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-2510-4266
Olyvia GleasonDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-9370-3324
Grace MeeganDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.
Jonathan G AmatrudaKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco (J.G.A., M.M.E., M.G.S.).ORCID 0000-0002-0118-7909
Julieta Moreno-VillagomezDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-6966-8795
Devin MahoneyDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-9059-1083
Jeffrey M TurnerDepartment of Internal Medicine, Division of Nephrology (J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-5733-949X
F Perry WilsonClinical and Translational Research Accelerator (F.P.W.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-2633-2412
Michelle M EstrellaKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco (J.G.A., M.M.E., M.G.S.).
Michael G ShlipakKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco (J.G.A., M.M.E., M.G.S.).
Veena S RaoDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.
Jeffrey M TestaniDepartment of Internal Medicine, Section of Cardiovascular Medicine (J.B.I.-M., B.S., C.M., O.G., G.M., J.M.-V., D.M., V.S.R., J.M.T.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-5285-0419
Maine Farmland Trust · USYale University · USDr. M.G.R. Educational and Research Institute · INGfK (United States) · USLipscomb University · USMahatma Gandhi University · INMahindra and Mahindra Limited (India) · INMexican Social Security Institute · MXTufts Medical Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Academic Training Program in NephrologyT32DK007219 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 1986 to 2022
$7.3M
Mechanism and Effects of Manipulating Chloride Homeostasis in Heart FailureR01HL139629 · NHLBI · YALE UNIVERSITY · PI JEFFREY M TESTANI · 2018 to 2026
$5.0M
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart FailureR01HL128973 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2015 to 2019
$3.8M
Kidney biomarkers in treatment for acute decompensated heart failureR01DK130870 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ESTRELLA, MICHELLE M, TESTANI, JEFFREY M · 2021 to 2025
$3.7M
Cardio-Renal Effects of Torsemide vs. Furosemide: A TRANSFORM-HF Mechanistic Sub-StudyR01HL148354 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2019 to 2022
$3.3M
Cardio-renal phenotype and prognosis in chronic heart failureK23HL114868 · NHLBI · YALE UNIVERSITY · PI TESTANI, JEFFREY M · 2012 to 2017
$845k
Urine galectin-3 as a biomarker of cardio-renal phenotype and prognosisR21HL143092 · NHLBI · YALE UNIVERSITY · PI RAO, VEENA, TESTANI, JEFFREY M · 2018 to 2019
$251k
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K23 HL114868NHLBI NIH HHS L30 HL115790NHLBI NIH HHS R01 HL128973NHLBI NIH HHS R01 HL139629NHLBI NIH HHS R01 HL148354NHLBI NIH HHS R21 HL143092NIDDK NIH HHS R01 DK130870NIDDK NIH HHS T32 DK007219
6 · The paper itself

Abstract

backgroundAnimal models implicate FGF-23 (fibroblast growth factor-23) as a direct contributor to adverse cardiorenal interactions such as sodium avidity, diuretic resistance, and neurohormonal activation, but this has not been conclusively demonstrated in humans. Therefore, we aimed to evaluate whether FGF-23 is associated with parameters of cardiorenal dysfunction in humans with heart failure, independent of confounding factors.

methodsOne hundred ninety-nine outpatients with heart failure undergoing diuretic treatment at the Yale Transitional Care Center were enrolled and underwent blood collection, and urine sampling before and after diuretics.

resultsFGF-23 was associated with several metrics of disease severity such as higher home loop diuretic dose and NT-proBNP (N-terminal pro-B-type natriuretic peptide), and lower estimated glomerular filtration rate, serum chloride, and serum albumin. Multivariable analysis demonstrated no statistically significant association between FGF-23 and sodium avidity measured by fractional excretion of sodium, or proximal or distal tubular sodium reabsorption, either before diuretic administration or at peak diuresis (

conclusionsFGF-23 was not meaningfully associated with any cardiorenal parameter in patients with heart failure. While our methods cannot rule out a small effect, FGF-23 is unlikely to be a primary driver of cardiorenal interactions.

Indexed as

SodiumAgedAged, 80 and overDiuresisDiureticsFemaleFibroblast Growth Factor-23Heart FailureHumansMaleMiddle AgedReninSodium Potassium Chloride Symporter InhibitorsDiureticsFibroblast Growth Factor-23ReninSodiumSodium Potassium Chloride Symporter Inhibitorschloridediureticheart failuremodels, animaloutpatient

Identifiers

PMID34689571
PMCPMC8782627
OpenAlexW3210483921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.